These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 12139204)

  • 1. Application of modeling and simulation to integrate clinical pharmacology knowledge across a new drug application.
    Gobburu JV; Sekar VJ
    Int J Clin Pharmacol Ther; 2002 Jul; 40(7):281-8. PubMed ID: 12139204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sponsors' and investigative staffs' perceptions of the current investigational new drug safety reporting process in oncology trials.
    Perez R; Archdeacon P; Roach N; Goodwin R; Jarow J; Stuccio N; Forrest A
    Clin Trials; 2017 Jun; 14(3):225-233. PubMed ID: 28345368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory considerations for evaluating the pharmacology and toxicology of antisense drugs.
    Black LE; Degeorge JJ; Cavagnaro JA; Jordan A; Ahn CH
    Antisense Res Dev; 1993; 3(4):399-404. PubMed ID: 8155981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Majority of Expedited Investigational New Drug Safety Reports Are Uninformative.
    Jarow JP; Casak S; Chuk M; Ehrlich LA; Khozin S
    Clin Cancer Res; 2016 May; 22(9):2111-3. PubMed ID: 26783289
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory considerations for oligonucleotide drugs: updated recommendations for pharmacology and toxicology studies.
    Black LE; Farrelly JG; Cavagnaro JA; Ahn CH; DeGeorge JJ; Taylor AS; DeFelice AF; Jordan A
    Antisense Res Dev; 1994; 4(4):299-301. PubMed ID: 7734946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigational new drug safety reporting requirements for human drug and biological products and safety reporting requirements for bioavailability and bioequivalence studies in humans. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2010 Sep; 75(188):59935-63. PubMed ID: 20879180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of pharmacometric analyses on new drug approval and labelling decisions: a review of 198 submissions between 2000 and 2008.
    Lee JY; Garnett CE; Gobburu JV; Bhattaram VA; Brar S; Earp JC; Jadhav PR; Krudys K; Lesko LJ; Li F; Liu J; Madabushi R; Marathe A; Mehrotra N; Tornoe C; Wang Y; Zhu H
    Clin Pharmacokinet; 2011 Oct; 50(10):627-35. PubMed ID: 21895036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An audience with Tatiana Prowell. Interviewed by Asher Mullard.
    Prowell T
    Nat Rev Drug Discov; 2014 Jun; 13(6):410-1. PubMed ID: 24875091
    [No Abstract]   [Full Text] [Related]  

  • 9. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review.
    Zhao P; Zhang L; Grillo JA; Liu Q; Bullock JM; Moon YJ; Song P; Brar SS; Madabushi R; Wu TC; Booth BP; Rahman NA; Reynolds KS; Gil Berglund E; Lesko LJ; Huang SM
    Clin Pharmacol Ther; 2011 Feb; 89(2):259-67. PubMed ID: 21191381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase 0 trials: a platform for drug development?
    Lancet; 2009 Jul; 374(9685):176. PubMed ID: 19616703
    [No Abstract]   [Full Text] [Related]  

  • 12. Why wasn't an investigational new drug (IND) application required before appropriate study?
    Maloney DM
    Hum Res Rep; 2004 Mar; 19(3):6-7. PubMed ID: 15139342
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical pharmacology aspects of sex-related drug products.
    Tran DC; Apparaju S; Yu C; Lee L; Kim H; Kim MJ
    Clin Pharmacol Ther; 2011 Jan; 89(1):26-8. PubMed ID: 21170068
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Causality Assessment in Premarketing Drug Clinical Trials: Regulatory Evolution in the USA and Ongoing Concerns.
    Goldman SA
    Drug Saf; 2016 Oct; 39(10):895-901. PubMed ID: 27473417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Investigational new drugs submitted to the Food and Drug Administration that are placed on clinical hold: the experience of the Office of Cellular, Tissue and Gene Therapy.
    Wonnacott K; Lavoie D; Fiorentino R; McIntyre M; Huang Y; Hirschfeld S
    Cytotherapy; 2008; 10(3):312-6. PubMed ID: 18418776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aggregation and analysis of secondary pharmacology data from investigational new drug submissions at the US Food and Drug Administration.
    Dodson A; Mi K; Russo DP; Scott C; Saulnier M; Snyder K; Racz R
    J Pharmacol Toxicol Methods; 2021; 111():107098. PubMed ID: 34229067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of exploratory investigational new drugs for translating radiopharmaceuticals into first-in-human studies.
    Schwarz SW; Oyama R
    J Nucl Med; 2015 Apr; 56(4):497-500. PubMed ID: 25766895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of secondary pharmacology assays received by the US Food and Drug Administration.
    Scott C; Dodson A; Saulnier M; Snyder K; Racz R
    J Pharmacol Toxicol Methods; 2022; 117():107205. PubMed ID: 35926773
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Innovative early development regulatory approaches: expIND, expCTA, microdosing.
    Robinson WT
    Clin Pharmacol Ther; 2008 Feb; 83(2):358-60. PubMed ID: 18091759
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Food and Drug Administration's early access and fast-track approval initiatives: how have they worked?
    Shulman SR; Brown JS
    Food Drug Law J; 1995; 50(4):503-31. PubMed ID: 10343017
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.